<DOC>
	<DOCNO>NCT02634580</DOCNO>
	<brief_summary>The primary hypothesis evolocumab ( AMG 145 ) SC well tolerate result great reduction LDL-C ezetimibe .</brief_summary>
	<brief_title>Goal Achievement After Utilizing Anti-PCSK9 Antibody Statin Intolerant Subjects-4</brief_title>
	<detailed_description>After screen subject subject meet inclusion/exclusion criterion randomize allocation ratio 2:2:1:1 4 group : evolocumab ( AMG 145 ) 420 mg administer subcutaneous injection monthly placebo pill daily ; evolocumab ( AMG 145 ) 140 mg administer subcutaneous injection every two week placebo pill mouth daily ; placebo 420 mg administer subcutaneous injection monthly ezetimibe 10 mg pill daily ; placebo 140 mg administer subcutaneous injection every two week ezetimibe 10 mg pill daily . Randomization stratify screen LDL-C level baseline statin use . Randomization occur within 5 - 10 day screen LDL-C evaluation use determine eligibility . Subjects low atypical statin dose continue take statin without dose adjustment duration blind portion study . After Week 12 , ezetimibe discontinue subject move open label dose evolocumab administer subcutaneous injection either every two week monthly standard care .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Male female ≥ 20 ≤ 80 year age Not statin low dose statin stable dose least 4 week . Subject LDLC goal History statin intolerance least 2 statin Lipid lower therapy stable prior enrolment least 4 week Fasting triglyceride ≤ 400 mg/dL NYHA III IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension Type 1 diabetes Poorly control type 2 diabetes Uncontrolled hypothyroidism hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Japanese</keyword>
	<keyword>High cholesterol</keyword>
	<keyword>Treatment high cholesterol</keyword>
	<keyword>Lowering cholesterol</keyword>
	<keyword>Lowering high cholesterol</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Statin intolerant</keyword>
</DOC>